美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Recro Pharma Inc

2.09

0.0000

成交量：- -

成交額：29.69萬

市值：9,742.44萬

市盈率：-0.91

高：2.09

開：2.09

低：2.09

收：2.09

52周最高：3.79

52周最低：1.38

股本：4,661.45萬

流通股本：3,668.56萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-2.2909

每股收益(LYR):-3.8956

淨資產收益率：1595.51%

總資產收益率：-5.38%

市淨率：-5.00

市盈率(LYR):-0.54

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Recro Pharma Inc

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.recropharma.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Recro Pharma, Inc.是一家處於發展階段的公司，於2007年11月15日與Recro第一製藥公司合併。公司於2008年8月31日更名為Recro製藥公司。該公司是一家專業製藥公司，通過兩個業務部門運營：急症護理部門和創收合同開發和製造部門或CDMO部門，通過該部門他們在喬治亞州的蓋恩斯維爾運營創收製造工廠。他們認為，他們可以為患者，處方者和付款人（例如他們的首要產品候選者，注射用美洛昔康）帶給醫院和相關急性護理市場有價值的治療選擇。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/REPH/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"REPH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"REPH\",,,,,undefined,":{"symbol":"REPH","market":"US","secType":"STK","nameCN":"Recro Pharma Inc","latestPrice":2.09,"timestamp":1647892800000,"preClose":2.09,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":36685639,"shares":46614535,"eps":-2.290947,"marketStatus":"休市中","change":0,"latestTime":"03-21 16:00:00 EDT","open":2.09,"high":2.09,"low":2.09,"amount":296933.780364,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.290947,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"symbolChange":{"newSymbol":"SCTL","executeDate":"2022-03-22"},"adr":0,"adrRate":0,"listingDate":1394168400000,"exchange":"NASDAQ","adjPreClose":2.09,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"REPH\",,,,,undefined,":{"symbol":"REPH","floatShares":36685639,"roa":"-5.38%","roe":"1595.51%","lyrEps":-3.895557,"shares":46614535,"dividePrice":0,"high":2.09,"amplitude":0,"preClose":2.09,"low":2.09,"week52Low":1.38,"pbRate":"-5.00","week52High":3.79,"institutionHeld":0,"latestPrice":2.09,"eps":-2.290947,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.290947,"open":2.09},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/REPH\",params:#limit:5,,,undefined,":[{"market":"US","date":"2022-03-22","symbol":"REPH","oldSymbol":"REPH","defaultRemindTime":1647955800000,"newSymbol":"SCTL","exchange":"NASDAQ","type":"symbolChange","dateTimestamp":1647921600000},{"market":"US","date":"2022-03-01","symbol":"REPH","fiscalQuarterEnding":"2021/12","expectedEps":-0.07,"name":null,"time":"盤後","type":"earning","dateTimestamp":1646110800000,"reportTimeType":"post","actualEps":-0.04},{"market":"US","date":"2021-11-09","symbol":"REPH","fiscalQuarterEnding":"2021/09","expectedEps":-0.05,"name":null,"time":"盤後","type":"earning","dateTimestamp":1636434000000,"reportTimeType":"post","actualEps":-0.07},{"market":"US","date":"2021-08-09","symbol":"REPH","fiscalQuarterEnding":"2021/06","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1628481600000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2021-05-06","symbol":"REPH","fiscalQuarterEnding":"2021/03","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1620273600000,"reportTimeType":"post","actualEps":-0.23}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"REPH\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"REPH\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.recropharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Recro Pharma, Inc.是一家處於發展階段的公司，於2007年11月15日與Recro第一製藥公司合併。公司於2008年8月31日更名為Recro製藥公司。該公司是一家專業製藥公司，通過兩個業務部門運營：急症護理部門和創收合同開發和製造部門或CDMO部門，通過該部門他們在喬治亞州的蓋恩斯維爾運營創收製造工廠。 他們認為，他們可以為患者，處方者和付款人（例如他們的首要產品候選者，注射用美洛昔康）帶給醫院和相關急性護理市場有價值的治療選擇。","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.018418},{"month":2,"riseRate":0.75,"avgChangeRate":0.018728},{"month":3,"riseRate":0.5,"avgChangeRate":0.15255},{"month":4,"riseRate":0.5,"avgChangeRate":0.067865},{"month":5,"riseRate":0.375,"avgChangeRate":-0.120099},{"month":6,"riseRate":0.625,"avgChangeRate":0.075849},{"month":7,"riseRate":0.5,"avgChangeRate":-0.018654},{"month":8,"riseRate":0.375,"avgChangeRate":0.041051},{"month":9,"riseRate":0.25,"avgChangeRate":-0.10177},{"month":10,"riseRate":0.125,"avgChangeRate":-0.058291},{"month":11,"riseRate":0.75,"avgChangeRate":0.068379},{"month":12,"riseRate":0.875,"avgChangeRate":0.060021}],"exchange":"NASDAQ","name":"Recro Pharma Inc","nameEN":"Recro Pharma"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"REPH\",market:\"US\",,,undefined,":null}}